MT-601 for Pancreatic Cancer

(PANACEA Trial)

This trial tests the safety and effects of a new treatment called MT-601 for individuals with pancreatic cancer. It examines the efficacy of different MT-601 doses administered during a chemotherapy break. Those with inoperable or metastatic pancreatic cancer, who have undergone specific chemotherapy treatments without cancer progression, may qualify for this trial. Participants must agree to provide certain blood samples for the study. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial information does not specify if you need to stop taking your current medications. However, if you are on systemic steroid therapy, you must stop it at least 7 days before starting the trial.

Research has shown that MT-601 is generally safe for patients. Studies found no serious side effects, such as severe reactions during infusion or nerve damage. One study reported that up to 84.6% of patients had their disease under control, indicating that MT-601 is usually well-tolerated. This treatment targets specific proteins in pancreatic cancer, allowing it to work effectively without significantly harming healthy cells. Although this trial remains in the early stages, current evidence suggests that MT-601 is a safe option for many patients.¹²³⁴⁵

Researchers are excited about MT-601 for pancreatic cancer because it uses a novel approach involving cell-based therapy. Unlike standard treatments like chemotherapy and radiation, which target cancer cells directly, MT-601 works by harnessing the power of modified immune cells, potentially offering a more targeted attack on the tumor. This treatment involves different doses, from 200 million to 1200 million cells, allowing researchers to find the most effective dose. The idea is that by boosting the body's own immune response, MT-601 might provide a more precise and potentially less harmful way to combat pancreatic cancer.

Studies have shown that MT-601 has a promising effect on pancreatic cancer. In earlier trials, 84.6% of patients achieved disease control, meaning their cancer did not worsen. The cancer shrank in 15.4% of patients, and 7.7% experienced a complete response, with no detectable cancer. Additionally, MT-601 stopped cancer growth in 61.5% of patients. These results suggest that MT-601 could effectively manage pancreatic cancer by controlling its growth. Participants in this trial will receive different doses of MT-601 to further evaluate its effectiveness and safety.¹²³⁶⁷